Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 101 | ETA2024 | Next issue

46th Annual Meeting of the European Thyroid Association (ETA) 2024

Oral Presentations

Oral Session 13: TED

Previous section
Oral Session 12: Clinical thyroid cancer research
Table of contents

ea0101op-13-01 | Oral Session 13: TED

VRDN-003, a full antagonist antibody to IGF-1R for thyroid eye disease (TED): phase 1 results show potential for subcutaneous administration

ea0101op-13-02 | Oral Session 13: TED

Response to teprotumumab is independent of race, ethnicity, and age

ea0101op-13-03 | Oral Session 13: TED

Abstract unavailable

ea0101op-13-04 | Oral Session 13: TED

Target-tissue immunophenotyping of patients with thyroid eye disease before and after therapy with steroids, tocilizumab and rituximab

ea0101op-13-05 | Oral Session 13: TED

Efficacy of teprotumumab on medical and surgical resistant don

ea0101op-13-06 | Oral Session 13: TED

Prognostic factors and outcomes of intravenous glucocorticoid pulse therapy in moderate-to-severe thyroid eye disease

ea0101op-13-07 | Oral Session 13: TED

Long-term outcome of graves’ orbitopathy following treatment with sirolimus (RAPAMYCIN)

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more